Pharmacotherapy of essential tremor
- PMID: 24385718
- PMCID: PMC3873223
- DOI: 10.4137/JCNSD.S6561
Pharmacotherapy of essential tremor
Abstract
Essential tremor (ET) is a common movement disorder but its pathogenesis remains poorly understood. This has limited the development of effective pharmacotherapy. The current therapeutic armamentaria for ET represent the product of careful clinical observation rather than targeted molecular modeling. Here we review their pharmacokinetics, metabolism, dosing, and adverse effect profiles and propose a treatment algorithm. We also discuss the concept of medically refractory tremor, as therapeutic trials should be limited unless invasive therapy is contraindicated or not desired by patients.
Keywords: essential tremor; gabapentin; pathogenesis; pregabalin; primidone; propranolol; topiramate.
References
-
- Elble RJ Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord. 2006;21(12):2052–61. - PubMed
-
- Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol. 2006;2(12):666–78. - PubMed
-
- Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13(suppl 3):2–23. - PubMed
-
- Jankovic J. Essential tremor: clinical characteristics. Neurology. 2000;54(suppl 4):S21–5. - PubMed
-
- Elble RJ. Essential tremor is a monosymptomatic disorder. Mov Disord. 2002;17(4):633–7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical